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1. Introduction
  Microspheres are free flowing powders consisting of 
encapsulated (drugs) spherical particles of size ideally 
less than 125p that can be suspended in aqueous vehicle 
and injected by an 18 or 16 number needle. Magnetic 
microspheres are supramolecular particles that are 
small enough to circulate through capillaries without 
producing embolic occlusion (<4 μm) but are sufficiently 
susceptible (ferromagnetic) to be captured in micro vessels 
and dragged into the adjacent tissues by magnetic fields 
of 0.5-0.8 Tesla (T). Methods of preparation of magnetic 
microspheres are namely phase separation emulsion 
polymerization (PSEP) and continuous solvent evaporation 
(CSE). The amount and rate of drug delivery via magnetic 
responsive microspheres can be regulated by varying (i) 
Size of microspheres; (ii)  Drug content; (iii) Magnetite 
content; (iv) Hydration state; (v) Drug release characteristic 
of carrier.
  The amount of drug and magnetite content of 
microspheres needs to be delicately balanced in order to 
design an efficient therapeutic system.
  Magnetic microspheres are characterized for different 
attributes such as (i) Particle size analysis including size 
distribution, surface topography, and texture etc. using 
scanning electron microscopy (SEM); (ii) Drug entrapment 
efficiency; (iii) % magnetite content; (iv) In vitro magnetic 
responsiveness; (v) Drug release.
  Targeting by magnetic microspheres i.e. incorporation 
of magnetic particles in to drug carriers (Polymers) and 
using an externally applied magnetic field is one way 
to physically direct these magnetic drug carriers to a 
desired site[1]. Drug targeting is the delivery of drugs to 
receptors or organ or any other specific part of the body to 
which one wishes to deliver the drug exclusively. Various 
nonmagnetic micro carriers (nanoparticles, microspheres 
Magnetic microspheres hold great promise for reaching the goal of controlled and site specific 
drug delivery. Magnetic microspheres as an alternative to traditional radiation methods which 
uses highly penetrating radiations that is absorbed throughout the body. Its use is limited by 
toxicity and side effects. Now days, several targeted treatment systems including magnetic field, 
electric field, ultrasound, temperature, UV light and mechanical force are being used in many 
disease treatments (e.g. cancer, nerve damage, heart and artery, anti-diabetic, eye and other 
medical treatments). Among them, the magnetic targeted drug delivery system is one of the 
most attractive and promising strategy for delivering the drug to the specified site. Magnetically 
controlled drug targeting is one of the various possible ways of drug targeting. This technology is 
based on binding establish anticancer drug with ferrofluid that concentrate the drug in the area of 
interest (tumor site) by means of magnetic fields. There has been keen interest in the development 
of a magnetically target drug delivery system. These drug delivery systems aim to deliver the 
drug at a rate directed by the needs of the body during the period of treatment, and target the 
activity entity to the site of action. Magnetic microspheres were developed to overcome two major 
problems encountered in drug targeting namely: RES clearance and target site specificity.
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and micro particles etc.) are successfully utilized for drug 
targeting but they show poor site specificity and are rapidly 
cleared off by RES (reticuloendothelial system) under 
normal circumstances. Magnetism plays an important role 
in these cases, magnetic particles composed of magnetite 
which are well tolerated by the body, magnetic fields are 
believed to be harmless to biological systems and adaptable 
to any part of the body[2]. Up to 60% of an injected dose 
can be deposited and released in a controlled manner in 
selected non reticuloendothelial organs. So magnetic micro 
carriers were developed to overcome two major problems 
encountered in drug targeting namely RES clearance 
and target site specificity. Magnetism has application in 
numerous fields like diagnostics, drug targeting, molecular 
biology, cell isolation, cell purification, hyperthermia, and 
radioimmunoassay[3].
2. Concept of targeting of non magnetic targeting 
versus magnetic targeting 
  Table 1 shows comparison of magnetic and non magnetic 
targeting.
3. Concept and principle behind magnetic targeting
  Magnetic drug delivery by particulate carriers is an 
efficient method of drug delivery to a localized disease 
site. A drug or therapeutic radioisotope is encapsulated in 
a magnetic compound; injected into patient’s blood stream 
& then stopped with a powerful magnetic field in the 
target area. Figure 1 shows representation of systemic drug 
delivery and magnetic targeting. Depending on the type 
of drug, it is then slowly released from magnetic carriers 
or confers a local effect, thus it reduces the loss of drug 
as freely circulating in body[4]. Drug targeting is a specific 
form of drug delivery where the drug is directed to its 
site action or absorption. This could be a particular organ 
structure, a cell, subsetor even an intercellular region. 
Figure 2 shows magnetic drug targeting.
Figure 1. Representation of systemic drug delivery and magnetic 
targeting.
Figure 2. Magnetic drug targeting.
3.1. Approaches of targeting
  Five different approaches of targeting are: (i) Chemical 
approach-prodrug; (ii) Compartment delivery; (iii) Natural 
targeting; (iv) Ligand mediated targeting; (v) Physical 
Table 1
Comparison of magnetic and non magnetic targeting.
S. No. Non magnetic targeting Magnetic targeting
1. Capillaries of human body are in microns, 
so one can easily target the capillaries 
of lungs, blood, liver etc by the use of 
microspheres.
Magnetic microspheres are injected into an artery that supplies a given site. As the 
microspheres would be selectively and magnetically localized at the capillary level, they 
would have free flow access through the large arteries. Thus the microspheres would serve 
as time-release capsule system sitting in the desired location. 
2. No magnetic field strength needed. A much lower magnetic field strength is necessary to restrict the microspheres at the slower 
moving flow velocities of blood in capillaries.
3. No effect of magnetic field. After removal of the magnetic field, the microspheres still continued to lodge at the target 
site, presumable because they had lodged in the vascular endothelium, penetrated in to the 
interstitial space, resulting in their retention.
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approach of targeting.
3.2. Principle of magnetic drug targeting & principle of 
magnetic drug targeting in cancer
  
  Principle of magnetic drug targeting & principle of 
magnetic drug targeting in cancer are shown in Figures 3 & 
4.      
  
Figure 3. Principle of magnetic drug targeting.
Figure 4. Principle of magnetic drug targeting in cancer.                             
          
4. Magnetic properties
  Magnetic particles for bio separation consist of one or 
more magnetic cores with a coating matrix of polymers, 
silica or hydroxyl apatite with terminal functionalized 
groups. The magnetic core generally consists either of 
magnetite (Fe3O4) or magnetite (gamma Fe2O3) with super 
paramagnetic or ferromagnetic properties. Some magnetic 
cores can also be made with magnetic ferrites, such as 
cobalt ferrite or manganese ferrite.
4.1. Super para magnetism
  Super Para magnetism is when the dipole moment of a 
single-domain particle fluctuates rapidly in the core due to 
the thermal excitation so that there is no magnetic moment 
for macroscopic time scales. Thus, these particles are non-
magnetic when an external magnetic field is applied but do 
develop a mean magnetic moment in an external magnetic 
field (Figure 5)[5].
a b
Figure 5. Super paramagnetic particles.
(a) under the influence of external magnetic field; (b) in absence of 
an external magnetic field, monodisperse particle distribution.
                                    
4.2. Ferromagnetism 
  Ferromagnetism means that the particles have a 
permanent mean magnetic moment. Here, the larger 
effective magnetic anisotropy suppresses the thermally 
activated motion of the core moments. Ferromagnetic 
particles are generally recommended for the separation of 
DNA/RNA (SiMAG/MP-DNA) (Figure 6)[6].       
                                       
a b
Figure 6. Ferromagnetic particles.
(a) under the influence of an external magnetic field; (b) in absence 
of an external magnetic field.
                                                   
5. Magnetite
  Also called as ferric ferrous oxide, tri iron tetra oxide, and 
black iron oxide. Magnetic iron oxide chemical formula 
FeOfe203 having a molecular weight of 231.55 with a 
chemical composition of Fe=72.36%, O=27.64%.
  The Ferro magnetic material when incorporated into 
microspheres makes them magnetically responsive, so that 
they can be concentrated to the desired site by applying 
some external magnetic field.
  To prepare magnetite, nitrogen gas flushed through 500 
mL round bottom flask fitted with condenser. Charged the 
flask with 8.9 g (0.1 mol) of goethite, 9.94 g (0.05 mol) of 
FeCl2.4H2O along with 250 mL deionized water. Added 50 
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mL of 2 M Sodium hydroxide. Reaction mixture was heated 
to reflux for 12 h. Its pH fell from 14 (orange) in to 8-9 
(black precipitates). Particles washed and air dried[7,8].
                
6. Materials used in magnetic microspheres
  Table 2 shows materials used in preparation of magnetic 
microspheres[9].
  
              
7. Factors regulating drug release from microspheres
  (1) The amount bind rate or drug delivery via magnetically 
responsive microspheres is regulated by varying the size of 
the microspheres, drug content, magnetic content, and their 
hydration state and drug release characters of the carrier.
  All the factors are inter-related.
  (2) Drug content depends on size. Drug content, which in 
turn is governed by solubility characters of drug and their 
method of preparation.
  (3) Hydration state of magnetic microspheres effects their 
distribution in the body.
  (4) The magnetic content and the magnitude of applied 
magnetic field govern the retention of microspheres at the 
target site.
  (5) In microspheres with high magnetic content, the 
external magnetic field strength required is less, but if 
high magnetic content is present than the space for drug 
available is less and hence the magnitude of magnetic 
content and drug should be delicately balanced to have 
effective therapeutic systems.
  Magnetic drug delivery by particulate carriers is a 
very efficient method of delivering a drug to a localized 
disease site. In magnetic targeting, a drug or therapeutic 
radioisotope is bound to a magnetic compound, injected 
into a patient’s blood stream, and then stopped with a 
powerful magnetic field in the target area[10]. Depending 
on the type of drug; it is then slowly released from the 
magnetic microspheres. It is thus possible to replace 
large amounts of freely circulating drug with much lower 
amounts of targeted magnetically to locally diseased sites, 
reaching effective up to several fold increased localized 
drug levels[11-13].
  Figure 7 shows various processes for preparation of 
magnetic particles viz. precursors, modification of 
the nanoparticles surface, targeted medicine, super 
paramagnetic particles preparation, functionalization by 
active biomolecules.
Figure 7. Processes of preparation of magnetic particles.
8. Methods of preparation of magnetic microspheres
8.1. Selection of drugs
  In the selection of a drug for formulation of magnetic 
microspheres, following points are taken into consideration: 
(i) The drug is so dangerous or labile that we cannot allow 
it to circulate freely in the blood stream. (ii) The agent is 
so expensive, that we cannot afford to waste 99.9% of it. 
(iii) Requires a selective, regional effect to meet localized 
therapeutic objective.
  Requires an alternative formulation essential to continue 
treatment in patient whose systemic therapy must be 
temporarily discontinued due to life threatening toxicity 
directed at selective organs[14].
8.2. Continuous solvent evaporation 
  In this method the drug and polymer (Carrier) are 
dissolved in appropriate volatile organic solvent and then 
magnetite (if magnetic microspheres) is added to this 
solution along with stirring in order to form a homogeneous 
suspension.  This suspension is added to an immiscible 
auxiliary solution along with vigorous stirring.  Now the 
volatile organic solvent is evaporated slowly at 22-30 °C to 
form microspheres. Microspheres are this centrifuged and 
freeze dried and stored at 4  °C[15-17].
8.3. Phase separation emulsion polymerization
  Homogenous aqueous suspension is prepared by adding 
Table 2
Materials used in preparation of magnetic microspheres.
S. No. Material used Types Examples
1. Synthetic polymers a) Biodegradable
b) Non biodegradable
Glycolides, Epoxy polymers,
polyanhydrides, Lactides
Polymethylmetharylate, Acrolein,Glycidyl methacrylate
2. Natural polymers a) Proteins
b) Carbohydrates
c) Chemically modified carbohydrates
Albumin, Gelatin, Collagen
Agarose, Starch, Chitosan
Polydextran, Polystarch
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albumin water-soluble drug and agent with magnetite in 
appropriate quantity of water (if magnetic microspheres). 
This aqueous suspension is then emulsified in the 
presence of suitable emulsifying agent to form spheres in 
emulsion.  This aqueous proteineous sphere thus formed 
in the emulsion are stabilized either by heating at 100-
150 °C or by adding hydrophobic cross linking agents 
like formaldehyde, glutraldehyde or 2-3 butadiene, 
microspheres thus produced are centrifuged out and 
washed either in ether or some other appropriate organic 
solvent to remove excess of oil.  Microspheres are freeze 
dried and stored at 4 °C[15-17].
8.4. Multiple emulsion method
  Water dispersible magnetite with a PEG/PAA coating 
was added to the BSA-containing inner water phase. 0.2 
mL of a 1 mg/mL BSA solution added to a 4 mL mixture of 
DCM and EA at a ratio of 3 to 1 containing 200 mg of PLGA 
(first w/o emulsion was prepared using a homogenizer 
(Polytron PT10-35; Kinematica, Luzern, Switzerland) in an 
ice bath at 26 000 r/min for 2.5 min). Fifteen mL of a 1% 
PVA solution poured directly into the primary emulsion 
and re-emulsified using the same homogenizer under 
the same conditions for another 2.5 min. W/o/w emulsion 
immediately poured into a beaker containing 85 mL of 
1% PVA solution and stirred in a hood under an overhead 
Propeller for 2 h, allowing the solvent to evaporate. 
Solidified microspheres harvested by centrifugation at 2 
500 r/min for 10 min and washed with distilled water three 
times (Figure 8)[18,19].
Figure 8. Preparation of microspheres by multiple emulsion method. 
8.5. Cross linking method
  Reagents used: Acetate buffer–used as solvent for the 
chitosan polymer; Glutraldehyde-used as the cross-linker; 
Sodium hydroxide solution-used as medium. 
  Synthesis of magnetic fluid: A 35% (w/v) ferrous sulfate 
solution, 54% (w/v) ferric chloride solution and 36% (w/v) 
sodium hydroxide solution were prepared using distilled 
water. Then the ferric salt and ferrous salt were mixed, 
stirred and heated. When the temperature reached 55 °C, 
the alkaline solution was added. The mixture was stirred for 
30 min, and then 5 g of polyethylene glycol-10000 (PEG-
10000) was added. The temperature was raised to 80 °C and 
maintained for 30 min. The mixture was then neutralized 
while cooling, and the magnetic fluid was prepared. 1% (w/
w) chitosan was dissolved in acetate buffer at pH 4.5. The 
dissolved chitosan was added drop wise on the magnetic 
fluid. Formed chitosan magnetic microspheres were 
washed with deionized water and soaked in 1, 3, and 5 mol 
% glutraldehyde solution for 2 h, and then washed with 
deionized water[20].
8.6. Alkaline co precipitation method
  Treat poly (acrylic acid–divinylbenzene) microspheres 
with dilute aqueous NaOH solution (0.5 M) for hours at 
suitable temperature to transform the carboxylic acid 
groups to sodium carboxylates and then washed thoroughly 
with water to remove the excess NaOH till neutral pH. 
Purged the microsphere suspension with nitrogen for 30 
min. To this suspension add an aqueous solution of FeCl3 
and FeCl2 that had been purged with nitrogen. Stirred 
the mixture overnight under nitrogen atmosphere for 
ion exchange. The resulting microspheres were washed 
repeatedly with water under nitrogen atmosphere to remove 
excess iron salts. Added drop wise an aqueous NaOH 
solution (3 M) to a suspension of the microspheres taken up 
with iron ions under nitrogen atmosphere to adjust the pH 
value to be >12. The mixture was then heated to 60 °C and 
kept for another 2 h. The resulting magnetic microspheres 
were suspended in an aqueous HCl solution (0.1 M) to 
transform the –COONa to –COOH, and then washed 
thoroughly with water to neutral pH, dried under vacuum at 
50 °C overnight, giving magnetic microspheres[21].
8.7. Inverse phase suspension polymerization method
  A 250 mL three-neck flask fitted with a mechanical 
stirrer used for performing the reaction. Continuous 
phase includes: 100 mL of castor oil and 10 mL of span 
80. Determined amount of itaconic acid (IA), Styrene (St), 
divinylbenzene (DVB) and N, N_ Methylene-bisacrylamide 
(BIS) dissolved completely in DMSO, and the organic phase 
was added drop wisely into the flask, with 70 °C heating 
using an oil bath. Ammonium persulfate (INITIATOR) added 
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drop wise using a syringe. The reaction proceeded for 8 h 
with continuous stirring. The resulting microspheres were 
separated by centrifugation. Further washed with diethyl 
ether and then by deionized water (Figure 9)[22].
Figure 9. Synthesis of P(St-IA-DVB) microspheres and MNPSID 
microspheres. 
P(St-IA-DVB) microspheres:  P(styrene-itaconic acid-
divinylbenzene) microspheres. 
MNPSID microspheres: Magnetic nanoparticles-coated P (St-IA-
DVB) microspheres. 
8.8. Sonochemical method
  The microspheres composed of iron oxide-filled 
and coated globular bovine serum albumin (BSA). The 
magnetic microspheres were prepared from BSA and iron 
penta carbonyl, or from BSA and iron acetate. Protein 
microspheres have a wide range of biomedical application, 
i.e. use as echo contrast agents for sonography. The 
microsphere were formed by either heat denaturation at 
various temperatures, or by cross linking with carbonyl 
compounds in the ether phase. Cross linking was done as: 
the microspheres are formed by chemically cross-linking 
cysteine residues of the protein with HO2 radical formed 
around a non-aqueous droplet. The chemical cross-linking 
is responsible for the formation of the microspheres and is 
a result of the chemical ejects of the ultrasound radiation 
on an aqueous medium.
  Two sonochemical methods for the fabrication of iron 
oxide nanoparticles were (i) Water as the solvent and (ii) 
Decalin as solvent.
  Decane and iron pentacarbonyl Fe(CO)5 (7.43U1034 M) 
were layered over a 5% w/v protein solution. The bottom 
of the high-intensity ultrasonic horn was positioned at 
the aqueous organic interface. The mixture was irradiated 
for 3 min, employing a power of W150 W/ 32cm with the 
initial temperature of 23 °C in the reaction cell. The pH 
was adjusted to 7.0 by adding HCl. This procedure was 
performed again with an aqueous solution of iron acetate, 
Fe(CH3CO2)2 95% (Sigma) (7.66U1033 M). After the synthesis, 
the products were separated from the unreacted protein 
and from the residues of iron acetate or iron pentacarbonyl 
by centrifugation (1 000 r/min for 5 min). The magnetic 
microspheres were washed a few times with sufficient 
volumes of water to remove the residues of the precursors[23-26].
8.9. Swelling and penetration method
  For swelling of polymer micro particles, 0.25 g of PS 
(Micron-size polystyrene) particles was mixed with 35 mL 
of a NMP/water solution in a specific v/v NMP (N-methyl-
2-pyrrolidone)-to-water ratio. In later preparations of 
magnetic microspheres, SDS (Sodium dodecyl sulfate) 
was added to the NMP/water solution. Whenever SDS 
was used, 0.025 g of SDS were added to each NMP/water 
solution. The NMP/water mixture with PS spheres was left 
soaking for 24 h at room temperature while stirring. 2.5 
mL of the superparamagnetic nanoparticle dispersion (24 
mg/mL or other specified concentration) was added to the 
mixture of PS sphere and NMP/water solution at 30 °C while 
shaking (at 140 r/min) for 1-5 days to allow the magnetic 
nanoparticles to penetrate into the interior of the PS 
particles. Afterwards, the polymer particles were separated 
from the solution by centrifugation. Finally, particles were 
sequentially washed with methanol, deionized water, and 
vacuum dried at room temperature for 1-2 days to yield the 
magnetic polymer microspheres[27].
8.10. Low-temperature hydrothermal method
  0.1 g Fe3O4 was dispersed in the aqueous glucose solution 
without additives, the hydrothermal reaction catalyzed only 
by Fe3O4 was kept at 180 °C for 5 h[28].
9. Comparison between CSE and PSEP
  For continuous solvent evaporation (CSE), wide 
range of chemotherapeutic agent would be covered by 
CSE technique, due to availability of organic solvent 
with varying polarity. For phase separation emulsion 
polymerisation (PSEP), a narrow range of chemotherapeutic 
agents can be incorporated into microspheres by PSEP 
because this process required aqueous solubility of the 
agent to be incorporated into the microspheres is an 
essential prerequisite for this technique. 
10. Characterization of magnetic microspheres
  (1) Particle size & size distribution: a) Sieving; b) 
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Microscopy; c) Coulter counter analysis; d) Laser diffraction 
analysis.
  (2) Surface characterization: a) High-resolution 
microscopy; b) Scanning electron microscopy; c) Scanning 
tunneling microscopy. 
  (3) Surface charge analysis: a) Micro electrophoresis; b) 
Laser Doppler anemometry. 
  (4) Density: a) Bulk density [Bulk density (ρb) (g/cm3) = M/
Vb. Where, M = mass of powder taken, Vb = bulk volume]; 
b) Tapped density [Tapped density (ρt) (g/cm3) = M/Vt. 
Where, M = weight of sample powder, Vt = tapped volume].
  (5) Flow properties: a) Angle of repose [Angle of Repose, θ 
= tan-1 h / r (Table 3)]; b) Hausner ratio [Hausner ratio = ρt/ 
ρb. Where, ρt = tapped density, ρb = bulk density].  
  (6) Drug release profiles: a) In vitro; b) In vivo. 
  (7) Surface area
  (8) Porosity
  (9) Hardness & friability
  (10) Drug content
  (11) Drug release profiles[29].
Table 3
 Flow properties (as per USP30-NF25 specifications).
S. No. Angle of repose Carr’s index (%) Hausner ratio Flow character
1. 25-30 <10 1.00-1.11 Excellent
2. 31-35 11-15 1.12-1.18 Good
3. 36-40 16-20 1.19-1.25 Fair
4. 41-45 21-25 1.26-1.34 Passable
5. 46-55 26-31 1.35-1.45 Poor
6. 56-65 32-37 1.46-1.59 Very Poor
7. >66 38 >1.60 Very Very Poor
11. Evaluation
11.1. Interaction study by TLC/ FTIR
 
11.1.1. IR Spectroscopic studies
  The IR spectra of the free drug and the microspheres 
were recorded. The identical peaks corresponding to the 
functional groups and albumin (BSA, Egg albumin, Human 
serum albumin) features confirm that neither the polymer 
nor the method of preparation has affected the drug 
stability.
11.1.2. Thin layer chromatographic studies
  The drug stability in the prepared microspheres can also 
be tested by the TLC method. The Rf values of the prepared 
microspheres can be compared with the Rf value of the 
pure drug. The values indicate the drug stability.
11.2. Surface topography by scanning electron microscopy 
(SEM)
  
  SEM of the microspheres shows the surface morphology of 
the microspheres like their shape and size.
11.3. Particle size distribution of prepared microspheres
  The size of the prepared microspheres can be measured 
by the optical microscopy method using a calibrated 
stage micrometer for randomly selected samples of all the 
formulations.
11.4. Drug entrapment capacity
  Efficiency of drug entrapment for each batch can be 
calculated in terms of percentage drug entrapment (PDE). 
Theoretical drug content can be determined by calculation 
assuming that the entire drug present in the polymer 
solution used gets entrapped in microspheres and no loss 
occurs at any stage of preparation of microspheres.
% Entrapment = (actual content / theoretical content) x 100
11.5. In vitro release dtudies
 
  In-vitro release studies can be performed according 
to USP XXII type I dissolution apparatus at suitable pH 
conditions. The temperature should be maintained at 
(37±0.5) °C and the rotation speed of 100 r/min. Then 5 mL 
of sample should be withdrawn at various time intervals 
and replenished with an equal volume of fresh dissolution 
media. The drug content in the sample can be analyzed 
spectrophotometrically at specific wavelength (nm).
11.5.1. Effect of pH on magnetic microspheres 
  Measurement of pH sensitive behavior is similar to the 
measurement of swelling kinetics of the microspheres. It 
is determined by the equilibrated swelling rate (ESR) at 
given pH data. ESR of the microspheres is measured by 
immersing dry and known weight of microspheres into 
buffer solution with different pH data for at least 1 h at 
room temperature. Then the microspheres are removed 
from the buffer solution and frequently weighed after 
trapped with a filter paper to remove excess of water on the 
surface. ESR is calculated from the following formula We/
Wd, where We is the weight of the solution in equilibrated 
swollen microspheres at each predetermined buffer solution 
with different pH data, the symbol of Wd is the same as 
defined earlier. The SR, (Ws + Wd)/Wd, is defined as the 
ratio of total weight of water in swollen microspheres to the 
weight of the dried microspheres, where Ws is the weight of 
adsorbed water and Wd is the weight of the microspheres at 
dry state[30]. 
11.5.2. In vitro drug release rate
  In vitro drug release rate determined by the following 
methods: (i) Dialysis method; (ii) Continuous column 
electron method; (iii) Dialysis method.
  The albumin microspheres were taken in a funnel; 3 
mL of phosphate buffer (7.3) was added. The mouth of the 
funnel was covered with cellophane paper and fastened to 
rubber band. The funnel was then inverted into a beaker 
containing 50 mL of phosphate buffer 7.3. 2.5 mL aliquots 
were withdrawn every half an hour and replaced with 2.5 
mL of fresh buffer. Aliquots were withdrawn over a period 
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of 10 h. The buffer in china dish was continuously stirred 
using a magnetic stirrer. The buffer was maintained at 37 
°C.
11.5.3. Continuous column elution method
  A continuous flow system similar to that described by 
Chien was used. Microspheres were immobilized on a 
column containing a fixed weight of glass wall (3.5 g) as 
support material and kept at 37 °C. They were subject to 
at intervals of half an hour. The amount of drug eluted was 
estimated.
11.6. Determination of solubility
  The solubility of particular microspheres in specific 
solution as microspheres or microcapsules to be soluble 
in that particular environment (water or phosphate buffers 
of pH 7.4) can be determined by taking excess quantity of 
microspheres in 50 mL vials filled with water. Shaked the 
vials on a magnetic stirrer. Filtered the solution through 
Whatmann paper no.1 and drug concentration determined 
at particular λ max value for the particular drug.
11.7. Solid state by DSC/XRD
  This test is done by an X-Ray diffractometer to find out 
the solid state of the drug, polymer and drug-polymer 
mixture and also to find out the solid state of the drug in 
the prepared albumin microspheres. The characterization of 
the micro particulate carrier is an important phenomenon, 
which helps to design a suitable carrier for the proteins, 
drug or antigen delivery. These microspheres have different 
microstructures. These microstructures determine the 
release and the stability of the carrier[31,32].
12. Advantages of magnetic microspheres
  (1) Incorporation of magnetically responsive materials into 
microspheres makes them susceptible to applied magnetic 
field, so that they are concentrated to the target site by 
application of magnetic field externally to that site. Due 
to this, rapid clearance of these microspheres by RES is 
prevented.
  (2) Difference occurs maximally in capillary network so 
efficient delivery of drug to diseased tissue is achieved.
  (3) Microspheres can transit into extra vascular space 
creating an extra vascular depot of drug for sustained 
release of drug within the targeted areas.
  (4) Increase of tumor targeting microspheres can be 
internalized by tumor cell due to its much-increased 
phagocytic activity as compared to normal cell. So the 
problem of drug resistance due to inability of drug to be 
transported across the cell membrane can be prevented.
  (5) Controlled and predictable rate of drug release with 
smaller doses of drug can be achieved.
  (6) Linear blood velocity in capillaries is 300 times less 
as compared to arteries, so much smaller magnetic field 
is sufficient to retain them in the capillary network of the 
target area.
  (7) Avoidance of acute toxicity directed against 
endothelium and normal parenchyma cell, controlled 
release within target tissue for intervals of 30 min to 30 h. 
as desired, adaptable to any part of body.
13. Disadvantages of magnetic microspheres
  (1) One of the major limitations of this system is the drug 
cannot be targeted to deep-seated organism in the body. 
This approach is confined to the targeting of drugs to the 
superficial tissues like skin, superficial tumors or the 
joints.
  (2) Thrombosis at the site of catheterization.
  (3) The unknown toxicity of magnetic beads.
 (4) The possible unwanted localization of the product in 
the liver and the regions of RES and the dangerous effect of 
self-flocculation of the magnetic particles causing vascular 
obstruction to vital organs in the body[33].
14. Storage
  Microsphere suspensions should not be frozen, as freezing 
is likely to cause irreversible aggregation. Cold storage (2-8 
°C) is recommended to inhibit microbial growth.  ‘Standard’ 
(non-protein coated) microsphere suspensions do not 
contain an antimicrobial agent. All suspensions should 
be handled using aseptic technique. Continuous rolling 
(e.g. 3-5 r/min on a cell culture roller) is recommended to 
keep microspheres in suspension, without generating foam 
(foam may cause particle loss through bead entrapment). 
If continuous rolling is not possible, particles should be 
thoroughly resuspended before use. Higher speed rolling 
(30-60 r/min for 2-4 h) is effective for the resuspension 
of settled material. Again, rolling speed is intended to 
effectively resuspend the beads without generation of 
foam[34].
 
15. Literature of drugs used in magnetic microspheres 
along with their polymers
  Table 4 shows drugs along with their polymers used in 
preparation of magnetic microspheres.
16. Marketed products
  Various preparations of magnetic microspheres are 
available which are characterized by their INCI names, 
size, oil abs, refractive index and density shown in Table 5.
17. Applications of magnetic microspheres
  Magnetic microspheres have wide range of applications. 
Various applications have been listed in Table 6.
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Table 4
Drugs and polymers used in preparation of magnetic microspheres.
S. No. Drug Polymer
1. Dexamethasone Albumin
2. Indomethacin Methylmethacrylate
3. Oxantrazole Chitosan
4. Diclofenac sodium Ethyl cellulose
5. 5-Fluorouracil Eudragit L100, Eudragit S100, Eudragit P4135F and Methylcellulose
6. Doxorubicin Poly (N-isopropylacrylamide)
7. Candida rugosa lipase Glycidyl methacrylate, ethylene glycol dimethacrylate and vinyl acetate
8. (Carboxymethyl)dextran Glycidyl methacrylate
9. Dexamethasone sodium phosphate Human serum albumin
10. Silicon (IV) phthalocyanine derivative Polyhydroxybutyrate-co-valerate (PHBHV) and poly(ecaprolactone) (PCL)
11. 5-fluorouracil Chitosan
12. Poly-l-lysine methotrexate Polyglutaraldehyde
13. Derivative of cyclophosphamide, Asta Z, Albumin
14. Nimesulide Polyvinyl alcohol,poly lactic acid
15. Ganciclovir Poly (d,L-lactide-co-glycolide (PLGA)
16. Verapamil hydrochloride Gelatin A and Chitosan
17. Cyclosporine A Poly(dl-lactide-co-glycolide)
18. Methotrexate Calcium pectinate
19. Pilocarpine nitrate Egg albumin
20. Doxorubicin Poly(acrylic acid)
21. Tamarind gum Chitosan
22. Lysozyme Tris(hydroxymethyl)aminomethane
23. Monoclonal anibodies Polystyrene
24. Cyclosporine Poly(caprolactone)
25. Metronidazole Gelatin
26. Lectin Human serum albumin and polystyrene
27. Doxorubicin loaded folate Poly(N-isopropylacrylamide)
Table 5 
Marketed formulations
S. No. Trade name INCI name Size
(毺m)
Oil abs
(g/g)
Refractive
index
Density
(g/in3)
1. EA-209 Ethylene/acrylic acid copolymer 10.0 0.60 1.51 2.6
2. Flo- beads SE-3107A(soft beads A) Ethylene /Methacrylate copolymer 11.0 0.62 1.49 3.1
3. Flo-beads SE-3207 B(Soft beads B) Ethylene/Methacrylate copolymer 11.6 0.62 1.49 3.9
4. BPD-800 HDl/trimethylol hexyllactyl cross polymer (AND silica)   6.5 0.63 1.52 6.4
5. BPD-500 HDl/trimethylol hexyllactyl cross polymer (AND silica) 12.0 0.65 1.52 9.5
6. BPD-500T HDl/PPG/Polycaprolactone cross polymer (AND silica) 13.5 0.58 1.52 8.2
7. BPA-500 Polymethyl methacrylate 10.0 0.55 1.49 5.2
8. BPA-500X Methyl methacrylate crosspolymer   7.0 0.58 1.49 6.7
9. MSP-822 Polymethyl methacrylate   7.0 0.55 1.49 6.2
10. MSP-825 Methyl methacrylate crosspolymer   8.0 0.57 1.49 6.7
11. MSP-930 Methyl methacrylate crosspolymer 11.0 2.00 1.49 5.0
12. SUNPMMA-H Methyl methacrylate crosspolymer 11.7 0.65 1.49 NA
13. TR-1 NYLON-6 13.0 1.12 1.53 4.0
14. TR-2 NYLON-6 20.0 1.41 1.53 3.5
15. POMP-605 NYLON-6   6.0 1.70 1.53 3.3
16. POMP-610 NYLON-6 11.0 1.80 1.53 2.8
17. SP-10 NYLON-12 10.0 0.60 1.53 6.2
18. SP-10L NYLON-12 10.0 0.62 1.53 5.2
19. SP-500 NYLON-12   5.0 0.60 1.53 4.7
20. CL-2080 Polyethylene 12.0 0.60 1.51 4.0
21. TOSPEARL® 1110A Polymethylsilsesqui oxane 11.0 0.50 1.41 4.5
22. TOSPEARL® 120A Polymethylsilsesqui oxane   1.2 0.57 1.41 6.5
23. TOSPEARL® 145A Polymethylsilsesquioxane   4.5 0.55 1.41 8.2
24. TOSPEARL® 2000B Polymethylsilsesquioxane   5.0 0.54 1.41 8.5
25. TOSPEARL® 3000 A Polymethylsilsesquioxane   5.0 0.54 1.41 7.0
10  Satinder Kakar et al./ Journal of Acute Disease (2013)1-12
Table 6
Applications of magnetic microspheres.
S. No. Application Drugs/Carriers presently in current investigation Reference
1. Tumor targeting Mitoxantrone, Paclitaxel [35]
2. Radioembolisation of liver and spleen tumors 186re/188re-glass Microspheres [36]
3. Magnetic control of pharmacokinetic parameters Insulin [37]
4. Magnetic bioseparation Dynabeads, used in isolation of mRNA, genomic DNA and proteins [38]
5. Changing the timing and/or extent of drug absorption 
in stomach or intestines
Diclofenac sodium [39]
6. Radiosynovectomy of arthritis joints 35s-colloid,  microspheres,169er.citrate [40]
7. Hyperthermia for treatment of cancer Cisplastin, Paclitaxel [41]
8. Detection of metastases in non-enlarged lymph nodes Supramagnetic iron oxide [42]
9. Labeled sandwich immunoassay Fluorogenic compound, AttoPhos(visual color generating compound) [43]
10. DNA detection (Figure 10) Dynabeads [44]
11. Bacteria detection Streptavidin coated magnetic beads [45]
12. Cell separation in microfluidics channel Dynabeads for separation of , proteins, nucleic acids, antigens and 
antibodies) or cells (e.g., blood cells, stems cells or bacteria)
[46]
13. Cell surface markers for the detection and localization 
of antigens and lectin receptors
separation of red blood cells (RBC) and lymphoid cells [47]
14. Isolation and functionality of cancer cells (eukaryotic 
cells)
Dynabeads for breast cancer cells [48]
15. Immunoprecipitation (isolation of various proteins) Dynabeads for liposaccharide binding proteins [49]
16. Isolation of cell compartments of eukaryotic cells Dynabeads for Golgi bodies,endosomal vesicles [49]
17. Removal of anti sperm antibodies and sperm cells Goat anti-human immunoglobulin [50]
18. T8 depletion in allogenic transplantation dynabeads for  bone marrow [50]
19. Magnetic separation of poly (A) mRNA Homogenization by mixture of guanidium thiocyanate and phenol-
chloroform
[51]
20. Magneto capture protein interaction assays (Figure 11) Ni-NTA (nitriloacetic acid) tagged magnetic agarose beads have 
been used for versatile magneto capture assays using 6xHis-tagged 
proteins
[52]
21. Drug targeting Elemental iron particles and activated carbon. Magnetic targeted 
carriers (1-2 毺m in size) can adsorb and desorbs pharmaceutical 
agents such as doxorubicin (DOX)
[53]
22. Contraceptive drug delivery Drug delivery is designed responsive to the changes in steroid 
secretion during menstrual cycle 
[29]
18. Conclusion
  Magnetism seems to be a common function of opening a 
new vista of a multi-barrier of multi-step drug delivery. 
Their main advantage is the targeting of drug using an 
external magnet, which can be accomplished very easily. 
They are relatively young drug delivery systems, having 
received attention from the early 1990s. In the early days 
of twentieth century, Paul Ehrlich envisioned his MAGIC 
BULLET CONCEPT-the idea that drugs reach the right site 
in the body, at the right time, at right concentration. It does 
not exert side effects, neither on its way to the therapeutic 
target, not at the target site, nor during the clearance 
process. Thus magnetic microspheres have the potential for 
these objectives. It is a challenging area for future research 
in the drug targeting so more researches, long term toxicity 
study, and characterization will ensure the improvement 
of magnetic drug delivery system. The future holds lot of 
promises in magnetic microspheres and by further study 
this will be developed as novel and efficient approach for 
targeted drug delivery system.
Cells/specimens
Immunomagnetic
Separation
Cell lysis
Hybrdization
Detection
Gene Probe Array
Gene Sequencing
Detection
Load on gel
Reaction
Terminaters
Strand Separation
Magnetic separation
Bead
Immobilization
Thermo Cycle
Biotin
PCR
Bacterial colony Suspension
Figure 10. Concept of DNA detection system use of magnetic 
separation-based sample processing and solid phase sequencing 
technologies.
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Figure 11. Magnetocapture protein interaction assays.
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